Vivoryon Therapeutics N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
03 mar 2015 - 08:00
Statutory name
Vivoryon Therapeutics N.V.
Title
Probiodrug: Data on Glutaminyl Cyclases (QCs) in its relation to Alzheimer's Disease (AD) published in Acta Neuropathologica
Comments
Strong correlation between QCs and AD pathology in human brain biopsies
underlines QC-inhibition as therapeutic approach
HALLE/SAALE, Germany, 3 March 2015 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), is pleased to note that a recently published paper in the journal Acta Neuropathologica[1] further details the role of Glutaminyl Cyclases (QCs) in AD pathology. The findings from the publicly funded research that included Prof Hans-Ulrich Demuth (as CSO of Probiodrug)[2] and Prof Steffen Roßner[3] show that besides QC, as shown earlier, its sister enzyme isoQC also contributes to Abeta pathology and neuroinflammation.
Related downloads
Date last update: 12 April 2026